RAPID MICRO BIOSYSTEMS, INC. 8-K

What Happened

• Rapid Micro Biosystems, Inc. (RPID) filed an 8-K disclosing the results of its Annual Meeting held May 21, 2026. A quorum was present with 37,099,555 of 41,267,511 Class A shares present in person or by proxy. Stockholders elected Richard Kollender as a Class II director (term through the 2029 annual meeting) and ratified PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for FY2026.

Key Details

• Total eligible Class A shares to vote: 41,267,511; shares present at meeting: 37,099,555.
• Director election (Richard Kollender): For 23,180,585; Withheld 1,998,525; Broker non-votes 11,920,445.
• Auditor ratification (PwC): For 37,096,030; Against 3,292; Abstaining 233; Broker non-votes 0.
• Filing date of the 8-K: May 28, 2026 (signed by CFO Sean Wirtjes).

Why It Matters

• Board composition: Electing Richard Kollender to a Class II director seat affects the company’s governance through the 2029 annual meeting and may influence strategic oversight.
• Auditor continuity: Ratification of PwC means the company will continue with its current independent auditor for fiscal 2026, which is relevant for continuity in financial reporting and audit processes.
• Vote detail: The large number of broker non-votes on the director election indicates some shares did not have discretion to vote on that matter at the meeting, which can affect the vote totals for contested governance items.